Podcasts about fasco

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39) CME information and select publications

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancerThe importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patientsResults from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interactionPresenters:Hope S. Rugo, MD, FASCODirector, Women's Cancer ProgramDivision Chief, Breast Medical OncologyProfessor, Department of Medical Oncology & Therapeutics ResearchCity of Hope Comprehensive Cancer CenterProfessor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast OncologyUniversity of California, San FranciscoSan Francisco, CaliforniaNerea Lopetegui-Lia, MDAssistant ProfessorDivision of Medical Oncology, Breast SectionDepartment of Internal MedicineThe Ohio State UniversityColumbus, OhioGet access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.Link to full program: https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FZW865. CME/MOC/AAPA/IPCE credit will be available until September 5, 2027.The March of Innovation in Prostate Cancer: Advancing Veteran Care With an Expanding and Personalized Treatment Arsenal In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Ramy Sedhom, MD, FASCO, University of Pennsylvania, Plainsboro, NJ Recorded on August 13, 2026 Ramy Sedhom, MD, FASCO Associate Professor, Clinical Medicine, Division of Hematology/Oncology Director, Program in Geriatric Oncology & Supportive Care Innovation and the Center for Cancer and Aging at the Penn Center for Cancer Care Innovation University of Pennsylvania Plainsboro, NJ In this episode, Dr. Ramy Sedhom from the University of Pennsylvania explores the role of bereavement support in oncology care. He discusses how clinicians can support patients’ families after a loss, recognize when grief may require additional intervention, and incorporate meaningful bereavement practices into routine care. The conversation also examines the impact of patient loss on healthcare professionals and offers practical strategies to reduce clinician moral distress and burnout. Tune in today for this thoughtful conversation! Mentioned on this episode: The Journal of Palliative Medicine: Top Ten Tips on Bereavement Care Man's Search for Meaning by Viktor E. Frankl It's OK That You're Not OK by Megan Devine Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

In today's episode, we welcomed Sagar Lonial, MD, FACP, FASCO, to discuss the significance of the August 2026 FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Dr Lonial is a professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as chief medical officer at Winship Cancer Institute of Emory University in Atlanta, Georgia. In the exclusive interview, Dr Lonial discussed the significance of the first approval of a CELMoD-based therapy for patients with multiple myeloma, detailed the key findings from the phase 3 EXCALIBER-RRMM trial (NCT04975997) that supported the regulatory decision, and expanded on how this combination regimen fits into the early relapse treatment paradigm.

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation sequencing receives relugolix/darolutamide with chemotherapy and experiences PSA decline that plateaus at approximately 1 ng/mL — Rana R McKay, MD, FASCO (10:29) CME information and select publications

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that progressed to metastatic HSPC with PTEN loss by next-generation sequencing of primary archival tissue from 2017 receives abiraterone for 2 years — Rana R McKay, MD, FASCO (8:26) CME information and select publications

Highlights from the PER® CME activity "Key Considerations for Health Equity and Patient-Centered Care in TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Aditya Bardia, MD, MPH, FASCO, and Kathryn E. Post, PhD, ANP-BC, discuss key drivers of disparities in outcomes for triple-negative breast cancer and strategies for patient-centered communication, from shared decision-making to managing treatment-related toxicity.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/key-considerations-for-health-equity-and-patient-centered-care-in-tnbcThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Gilead Sciences, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts William Gradishar, MD, FASCO, FACP; and Kamel Abou Hussein, MD; discuss optimizing first-line treatment selection in metastatic triple-negative breast cancer (TNBC) with emerging antibody-drug conjugates (ADCs) and biomarker-guided strategies.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/from-trials-to-the-clinic-incorporating-new-advances-in-metastatic-tnbcThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Gilead Sciences, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; and Ulka Vaishampayan, MD, FASCO; discuss emerging antibody-drug conjugates and bispecific agents in lung, breast, endometrial, and prostate cancers, and how these agents may shift the therapeutic landscape in these disease.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/adcs-and-bispecific-antibodies-across-solid-tumors-integrating-new-targets-new-data-and-new-decisions-xqkuThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from BioNTech.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Ghassan Abou-Alfa, MD, JD, MBA, PhD (hc), Riad Salem, MD, MBA, Rachna T. Shroff, MD, MS, FASCO, and Arndt Vogel, MD, PhD discuss closing clinical practice gaps in hepatobiliary cancer with emerging immunotherapies and delivery innovations.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/medical-crossfire-closing-clinical-practice-gaps-in-hepatobiliary-cancer-with-emerging-immunotherapies-and-delivery-innovations-h754 This podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AstraZeneca Pharmaceuticals.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; and Jason Aboudi Mouabbi, MD; discuss the latest data to inform management of patients with early-stage triple negative breast cancer (TNBC).Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/show-me-the-data-redefining-treatment-paradigms-in-triple-negative-breast-cancer-across-the-disease-continuum-h5knThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; BioNTech; Daiichi Sankyo, Inc.; and Merck Sharp & Dohme LLC.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UHM865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies[JAC_Logo] In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

Highlights from the PER® CME activity "Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD; and Ebony R. Hoskins, MD, FACOG, discuss several cases of endometrial cancer using biomarkers to drive treatment decisions.Earn CME credit by completing the full accredited activity (available through June 26, 2027):https://www.gotoper.com/iog26endometrial-activityThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from BioNTech; Eisai, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In this podcast, experts Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Nadia Harbeck, MD; and Heather McArthur, MD, MPH; discuss updates from the SERENA-6, evERA, PREcoopERA, and TRAK-ER trials of oral selective estrogen receptor degraders (SERDS) in patients with hormone receptor–positive/HER2-negative (HR+/HER2–) early, advanced, and metastatic breast cancer (MBC). These results were presented at European Society for Molecular Oncology (ESMO) Breast 2026.

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital

In this episode of the PQI Podcast, we sit down with Brian I. Rini, MD, FASCO, Ingram Professor of Medicine at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, and co-host of the popular GU oncology podcast Uromigos, for a conversation on the evolution of genitourinary oncology and GU cancer care. Dr. Rini shares how mentorship and early exposure to GU oncology helped shape his career path and reflects on the rapid transformation of treatment over the years. The discussion explores his experience in clinical research and drug development, including involvement in therapies that have led to FDA approvals and changed the treatment landscape for patients with renal cell carcinoma. The episode also highlights the complexity and diversity of GU cancers, the importance of multidisciplinary collaboration across oncology care teams, and the future of innovation in GU cancer research. Dr. Rini additionally discusses the value of education and communication within oncology through his work with Uromigos, helping bring meaningful and practical Listen to Uromigos: https://www.uromigos.org/

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Charles D. Blanke, MD, FACP, FASCO, a professor of medicine in the School of Medicine at the Oregon Health & Science University (OHSU) Knight Cancer Institute in Portland.Drs Camidge and Blanke discuss Dr Blanke's unique career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying. A Type 1 diabetes diagnosis directed Dr Blanke toward an interest in internal medicine and oncology. During his fellowship and early faculty days, he established a reputation for his hard work pursuing research opportunities, even when initial projects were unsuccessful.Blanke's most transformative scientific achievement occurred at OHSU, where he spearheaded the use of Imatinib (Gleevec) for the management of gastrointestinal stromal tumor (GIST). By targeting the KIT mutation, this research turned a previously untreatable malignancy into one with a high response rate, marking a landmark moment for personalized oncology.Equally significant in Dr Blanke's career is his role in medical aid in dying. Practicing in Oregon, the first state to legalize the option, he has written hundreds of prescriptions for patients with terminal diseases. Blanke views medical aid in dying as a vital extension of patient care.As the former chair of SWOG, Dr Blanke modernized clinical research by introducing term limits, increasing access to clinical trials among, and championing the development of pragmatic trials with broader patient eligibility criteria. Throughout his tenure, he emphasized the importance of patient advocacy and the altruistic nature of cooperative research. Having recently stepped down from his leadership at SWOG, he intends to focus his future efforts on patient rights and medical aid in dying advocacy.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BWH865. CME/MOC/AAPA/IPCE credit will be available until May 5, 2027.Raising the CAP on Lymphoma Care: Community–Aligned Principles for Integrating CELMoDs Into Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BWH865. CME/MOC/AAPA/IPCE credit will be available until May 5, 2027.Raising the CAP on Lymphoma Care: Community–Aligned Principles for Integrating CELMoDs Into Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BWH865. CME/MOC/AAPA/IPCE credit will be available until May 5, 2027.Raising the CAP on Lymphoma Care: Community–Aligned Principles for Integrating CELMoDs Into Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 2: Future Directions in the Use of Oral SERDs for HR-Positive, HER2-Negative BC — Erica Mayer, MD, MPH, FASCO CME information and select publications

In this podcast, experts Adam Brufsky, MD, PhD; Kamel Abou Hussein, MD; and Priyanka Sharma, MD, FASCO, discuss personalizing care in early-stage triple-negative breast cancer (TNBC) and the evolving first-line strategies and their implications for downstream sequencing in metastatic TNBC.

In this podcast, experts Ann H. Partridge, MD, MPH; Saranya Chumsri, MD; and William J. Gradishar, MD, FASCO, FACP, discuss the roles of adjuvant chemotherapy and CDK4/6 inhibitors and neoadjuvant checkpoint inhibitors for patients with early-stage, hormone receptor–positive breast cancer.

In this podcast, experts Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Paolo Tarantino, MD, PhD; and Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS; discuss and debate recently published results of pivotal clinical trials in early-stage, HER2-positive breast cancer and their implications for patient care.

In this podcast, experts Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; and Banu Arun, MD, FASCO; discuss how genetic testing drives breast cancer management from screening and surgical decisions to targeted systemic therapies.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCY865. CME/MOC/AAPA/IPCE credit will be available until March 22, 2027.From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer with the International Myeloma Foundation and professor in the Applied Cancer Research and Drug Discovery Division of the Translational Genomics Research Institute, has spent more than 25 years advancing the treatment of multiple myeloma. In this episode, he breaks down how improved survival, evolving frailty assessments, and the rise of therapies like CAR T and bispecific antibodies are reshaping care for an aging population, and he highlights the growing emphasis on quality of life, caregiver support, and expanding clinical trial access.

In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in advanced non–small cell lung cancer (NSCLC).

In this podcast, experts Manish A. Shah, MD, FASCO; Syma Iqbal, MD; and Haeseong Park, MD, MPH; discuss novel combinations of targeted therapy, immunotherapy, and chemotherapy to treat resectable and unresectable gastroesophageal adenocarcinomas.